Flagship explainer
What drives Agios Pharmaceuticals, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$413M | FY2025 |
| |
| Income before tax | −$414M | FY2025 |
|
| Operating income | −$472M | FY2025 |
|
| $54M | FY2025 |
| |
| Ending assets | $1.3B | FY2025 |
|
| Beginning assets | $1.7B | FY2024 |
|
| $1.2B | FY2025 |
| |
| $1.5B | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001439222-26-000025